ClinicalTrials.gg
TerminatedNCT00630487IGHDUpdated Mar 4, 2013Results posted

Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone Deficiency

A Phase 3 interventional study of Placebo and Somatropin in Growth Hormone Deficiency, sponsored by Pfizer. Terminated at 2 sites in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-03-04.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Enrollment
56th of 60
9 · median 66
Started
2008
with 4 others
Phase 3
23 of 60
2 open now
Registered
25th of 60
by date
Lead sponsor
5 of 60
Pfizer

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 56th largest by enrollment, is one of 5 that started in 2008, is one of 23 in phase 3, and was the 25th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

The study will investigate the effect on growth hormone replacement in patients with isolated growth hormone deficiency on body composition, especially visceral fat mass.

Read the detailed description

The study was terminated on 15-Dec-2008 due to poor recruitment. Although 9 Patients were enrolled, no patient was randomized nor treated with somatropin. No safety reasons contributed to the termination.

03

Conditions studied

  • Growth Hormone Deficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females between 18 and 65 years of age
  • Isolated growth hormone deficiency

Exclusion criteria

Exclusion Criteria:

  • Isolated growth hormone deficiency by childhood onset
  • Diabetes mellitus type 1 or 2
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
9 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Active comparator
    Verum

    Drug: Somatropin

Interventions

  • DrugPlacebo

    Patients of Placebo Group will be treated with placebo sub-cutaneous in the same way as Somatropin during the double blind treatment phase. To maintain blind subject will be measured in the same way as the treatment group for IGF-I- Levels. Central lab will randomize placebo patients to dose change or maintenance of dose. This will ensure continued blinding of the study to patients and personnel.

  • Fixed doses for patients: MALE: \< 45y 0,4 mg, \> 45y 0,2mg FEMALE: \< 45y 0,5mg, \>45y 0,3mg. for the first 4 weeks half of the dose will be given. After that dose will be increased to the targeted maintenance dose according to IGF-I Levels +/- 2 SD of age adjusted reference range. In case of side effects dosage will remain on half-dose (during the first 4 weeks) or reduced to half dose (after the first 4 weeks). At week 52 patients have the opportunity to switch to open label study restarting with half the given fixed dose which will be adjusted to full dose after 4 weeks.

06

What researchers measure

Primary outcomes

  1. Change of Visceral Fat Mass Assessed by Magnetic Resonance Imaging Scanning (MRI)

    Fat measurements carried out with the subjects lying in a supine position in a MRI scanner. Measurements of regional body fat obtained between the level of the coccygeal bone and the 2nd or 3rd lumbar vertebra.

    Time frame: Baseline, 52 weeks

Secondary outcomes

  1. Change in Visceral Fat Mass in Subgroups

    Change in visceral fat mass in subgroups. Subgroup 1: isolated GHD due to surgery and/or irradiation of pituitary adenoma and suprasellar tumors. Subgroup 2: history of traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH).

    Time frame: Baseline, 52 weeks, 78 weeks

  2. Change From Baseline in Anthropometric Parameters (Height)

    Time frame: Baseline, 52 weeks, 78 weeks

  3. Change From Baseline in Anthropometric Parameters (Weight)

    Time frame: Baseline, 52 weeks, 78 weeks

  4. Change From Baseline in Anthropometric Parameters (Waist Circumference)

    Time frame: Baseline, 52 weeks, 78 weeks

  5. Change From Baseline in Alertness (Testbatterie Zur Aufmerksamkeitsprüfung [TAP]) and Memory (Auditory Verbal Learning Test [AVLT])

    Alertness: software-based neuropsychological assessment for response time and errors. Memory: analysis of learning and retention using 5-trial presentation of 15-word list (A), single presentation of interference list (B), 2 postinterference recall trials - 1 immediate, 1 delayed - and recognition of the target words with distractors (C). Performance variables were immediate word span under overload conditions, final acquisition level, amount learned in 5 trials, interference, delayed recall, and recognition (implicit learning).

    Time frame: Baseline, Week 52, Week 78

  6. Change From Baseline in Blood Pressure

    Blood pressure was measured seated, the subject's arm supported at the level of the heart, and recorded to the nearest mm Hg. The same arm (preferably the dominant arm) was used throughout the trial. The subject was seated for 5 minutes before the blood pressure was obtained. Use of an automated device could have been used for measuring blood pressure.

    Time frame: Baseline, Week 52, Week 78

  7. Change From Baseline in Heart Rate

    The use of an automated device for measuring pulse rate was acceptable, although, when done manually, pulse rate was measured in the brachial/radial artery for at least 30 seconds.

    Time frame: Baseline, Week 52, Week 78

  8. Change in Executive Function and Memory in Subgroups

    Change in executive function and memory in subgroups. Subgroup 1: isolated Growth Hormone Deficiency (GHD)due to surgery and/or irradiation of pituitary adenoma and suprasellar tumors. Subgroup 2: history of traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH). Median reaction time, the total number of errors, the number of omissions and the number of false positive reactions.

    Time frame: Baseline, Week 52, Week 78

  9. Change From Baseline in Safety Laboratory Assessments

    Prespecified safety laboratory assessments evaluated for change or no change from baseline. Possible responses were Yes/No.

    Time frame: Baseline, Week 52, Week 78

  10. Change From Baseline in Homeostasis Model Assessment (HOMA)-Index

    HOMA index is calculated by 1 of 2 methods: HOMA-Index = fasting insulin measured in microunits per milliliter (µU/ml) times fasting glucose measured in milligrams per deciliter mg/dl) divided by 405 or HOMA-Index = fasting insulin (µU/ml) times fasting glucose measured in millimoles per liter (mmol/l) divided by 22.5.

    Time frame: Baseline, Week 52, Week 78

  11. Change From Baseline in Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA)

    Participant self administered questionnaire consisting of 25 items that evoke yes or no answers. A score of 1 is given to each item affirmed and these are summed to give the total score. The maximum score is 25, which represents a poor quality of life. The minimum score is 0, which represents a good quality of life.

    Time frame: Baseline, Week 52, Week 78

  12. Change From Baseline in Short Form (36) Health Survey (SF36)

    Participant self administered questionnaire that measures each of the following eight health concepts: Physical Functioning (PF); Role-Physical (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role-Emotional (RE); Mental Health (MH) as well as a reported Health Transition item (HT). Scale range 0 to 100, higher scores indicate a better health-related quality of life.

    Time frame: Baseline, Week 52, Week 78

  13. Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D)

    Participant self-administered questionnaire EQ-5D, a 2 part generic health status instrument. The first part consists of 5 descriptors of current health state: mobility, self care, usual activities, pain/discomfort and anxiety/depression. Scores are assigned on a three-level scale (1= no problem, 2= some problem, 3= extreme problem). The second part was an overall rating of the participant's current health state using a 20 cm Visual Analogue Scale (EQ-VAS) with endpoints labelled 'best imaginable health state' and 'worst imaginable health state'.

    Time frame: Baseline, Week 52, Week 78

  14. Change From Baseline in Cardiovascular Risk Factors

    Change in values of laboratory tests indicative of possible cardiovascular risk factors: high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides, N-terminal pro brain natriuretic peptide)

    Time frame: Baseline, Week 52, Week 78

07

Results

Posted Jan 27, 2011

Participant flow

Study Initiation and Completion Dates: 26 May 2008 to 17 October 2008. The study was terminated prematurely.

Participant flow — Overall Study
MilestonePlaceboSomatropin
Started00
Completed00
Not completed00

Outcome measures

PrimaryChange of Visceral Fat Mass Assessed by Magnetic Resonance Imaging Scanning (MRI)

Fat measurements carried out with the subjects lying in a supine position in a MRI scanner. Measurements of regional body fat obtained between the level of the coccygeal bone and the 2nd or 3rd lumbar vertebra.

Time frame:
Baseline, 52 weeks

No measurements were reported for this outcome.

SecondaryChange in Visceral Fat Mass in Subgroups

Change in visceral fat mass in subgroups. Subgroup 1: isolated GHD due to surgery and/or irradiation of pituitary adenoma and suprasellar tumors. Subgroup 2: history of traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH).

Time frame:
Baseline, 52 weeks, 78 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Anthropometric Parameters (Height)
Time frame:
Baseline, 52 weeks, 78 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Anthropometric Parameters (Weight)
Time frame:
Baseline, 52 weeks, 78 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Anthropometric Parameters (Waist Circumference)
Time frame:
Baseline, 52 weeks, 78 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Alertness (Testbatterie Zur Aufmerksamkeitsprüfung [TAP]) and Memory (Auditory Verbal Learning Test [AVLT])

Alertness: software-based neuropsychological assessment for response time and errors. Memory: analysis of learning and retention using 5-trial presentation of 15-word list (A), single presentation of interference list (B), 2 postinterference recall trials - 1 immediate, 1 delayed - and recognition of the target words with distractors (C). Performance variables were immediate word span under overload conditions, final acquisition level, amount learned in 5 trials, interference, delayed recall, and recognition (implicit learning).

Time frame:
Baseline, Week 52, Week 78

No measurements were reported for this outcome.

SecondaryChange From Baseline in Blood Pressure

Blood pressure was measured seated, the subject's arm supported at the level of the heart, and recorded to the nearest mm Hg. The same arm (preferably the dominant arm) was used throughout the trial. The subject was seated for 5 minutes before the blood pressure was obtained. Use of an automated device could have been used for measuring blood pressure.

Time frame:
Baseline, Week 52, Week 78

No measurements were reported for this outcome.

SecondaryChange From Baseline in Heart Rate

The use of an automated device for measuring pulse rate was acceptable, although, when done manually, pulse rate was measured in the brachial/radial artery for at least 30 seconds.

Time frame:
Baseline, Week 52, Week 78

No measurements were reported for this outcome.

SecondaryChange in Executive Function and Memory in Subgroups

Change in executive function and memory in subgroups. Subgroup 1: isolated Growth Hormone Deficiency (GHD)due to surgery and/or irradiation of pituitary adenoma and suprasellar tumors. Subgroup 2: history of traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH). Median reaction time, the total number of errors, the number of omissions and the number of false positive reactions.

Time frame:
Baseline, Week 52, Week 78

No measurements were reported for this outcome.

SecondaryChange From Baseline in Safety Laboratory Assessments

Prespecified safety laboratory assessments evaluated for change or no change from baseline. Possible responses were Yes/No.

Time frame:
Baseline, Week 52, Week 78

No measurements were reported for this outcome.

SecondaryChange From Baseline in Homeostasis Model Assessment (HOMA)-Index

HOMA index is calculated by 1 of 2 methods: HOMA-Index = fasting insulin measured in microunits per milliliter (µU/ml) times fasting glucose measured in milligrams per deciliter mg/dl) divided by 405 or HOMA-Index = fasting insulin (µU/ml) times fasting glucose measured in millimoles per liter (mmol/l) divided by 22.5.

Time frame:
Baseline, Week 52, Week 78

No measurements were reported for this outcome.

SecondaryChange From Baseline in Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA)

Participant self administered questionnaire consisting of 25 items that evoke yes or no answers. A score of 1 is given to each item affirmed and these are summed to give the total score. The maximum score is 25, which represents a poor quality of life. The minimum score is 0, which represents a good quality of life.

Time frame:
Baseline, Week 52, Week 78

No measurements were reported for this outcome.

SecondaryChange From Baseline in Short Form (36) Health Survey (SF36)

Participant self administered questionnaire that measures each of the following eight health concepts: Physical Functioning (PF); Role-Physical (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role-Emotional (RE); Mental Health (MH) as well as a reported Health Transition item (HT). Scale range 0 to 100, higher scores indicate a better health-related quality of life.

Time frame:
Baseline, Week 52, Week 78

No measurements were reported for this outcome.

SecondaryChange From Baseline in European Quality of Life-5 Dimensions (EQ-5D)

Participant self-administered questionnaire EQ-5D, a 2 part generic health status instrument. The first part consists of 5 descriptors of current health state: mobility, self care, usual activities, pain/discomfort and anxiety/depression. Scores are assigned on a three-level scale (1= no problem, 2= some problem, 3= extreme problem). The second part was an overall rating of the participant's current health state using a 20 cm Visual Analogue Scale (EQ-VAS) with endpoints labelled 'best imaginable health state' and 'worst imaginable health state'.

Time frame:
Baseline, Week 52, Week 78

No measurements were reported for this outcome.

SecondaryChange From Baseline in Cardiovascular Risk Factors

Change in values of laboratory tests indicative of possible cardiovascular risk factors: high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides, N-terminal pro brain natriuretic peptide)

Time frame:
Baseline, Week 52, Week 78

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo———
Somatropin———

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboSomatropinTotal
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSomatropinTotal
08

Study locations

2 sites
  • Pfizer Investigational Site
    Bad Aibling, 83043, Germany
  • Pfizer Investigational Site
    Muenchen, 80804, Germany
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2008
First posted
Mar 7, 2008
Start
May 2008
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Jan 27, 2011
Last update
Mar 4, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00630487
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 7, 2008
Start date
May 2008
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Jan 27, 2011
Last update
Mar 4, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion